Neuropathic pain

Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024
Lithium, UGT, Risk, Digoxin, Shanda, Hypotension, FDA, SGLT1, Type 2 diabetes, Acute kidney injury, Congress, Pyelonephritis, Conference, Fever, Ketoacidosis, Pregabalin, Pregnancy, Pain, Assessment, Gabapentin, Tenderness, New Drug Application, Amber Grid, HCM, Common, SGLT2, PROGRESS, Hypertrophic cardiomyopathy, Diabetes, Kidney, Heart failure, Dialysis, History, Patient, Prescription, Type, Neuropathic pain, Webcast, Insulin, T2DM, EGFR, Erythema, T1DM, Hypoglycemia, Partnership, Contraindication, Diarrhea, NDA, Incidence, Swelling, Urinary tract infection, Hospital, Chronic kidney disease, Internationalized domain name, Metabolic acidosis, Creatinine, Growth, Lactation, Pharmaceutical industry

THE WOODLANDS, Texas, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives, today announced a business and pipeline update at the 42nd Annual J.P. Morgan Healthcare Conference taking place January 8-12, 2024.

Key Points: 
  • THE WOODLANDS, Texas, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives, today announced a business and pipeline update at the 42nd Annual J.P. Morgan Healthcare Conference taking place January 8-12, 2024.
  • “Lexicon achieved major advancements in 2023 in its business and pipeline of pharmaceutical innovations,” said Lonnel Coats, chief executive officer and director of Lexicon.
  • The company will also focus on ensuring a strong ongoing awareness of INPEFA in the medical community through medical publications and congress presence.
  • Company to Present at J.P. Morgan Healthcare Conference Thursday, January 11, 2024 at 10:30am PST (1:30pm ET)
    Lonnel Coats, Lexicon’s chief executive officer, will make a company presentation.

Bausch + Lomb Receives FDA Approval for TENEO™ Excimer Laser Platform for Myopia and Myopic Astigmatism LASIK Vision Correction Surgery

Retrieved on: 
Monday, January 8, 2024
FDA, General Health, Optical, Health, IOP, Telecanthus, Patient, Ophthalmology, Failure, Corneal topography, Food, Autoimmune disease, Contraindication, Risk, Floater, Sale, Near-sightedness, CTK, Pain, Retinal detachment, User, Bleeding, Surgeon, Diabetes, Dry, Eye, Side, Dry eye syndrome, Posture, Laser, Visual acuity, Neuropathic pain, Engineering, Infection, Use, Keratoconus, Safety, Magnetic resonance, Bausch & Lomb, Glaucoma, Hospital

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. Food and Drug Administration (FDA) has approved the TENEO Excimer Laser Platform for laser-assisted in situ keratomileusis (LASIK) vision correction surgery for myopia and myopic astigmatism (nearsightedness and nearsightedness with astigmatism)*.

Key Points: 
  • Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. Food and Drug Administration (FDA) has approved the TENEO Excimer Laser Platform for laser-assisted in situ keratomileusis (LASIK) vision correction surgery for myopia and myopic astigmatism (nearsightedness and nearsightedness with astigmatism)*.
  • This feature helps to ensure the laser ablation pattern is not negatively impacted by a patient's eye movement and helps achieve outstanding post-operative outcomes.
  • The platform’s high-speed laser operates at 500Hz, the fastest ablation time of all excimer lasers available in the United States at approximately 1.2 seconds per diopter.
  • “FDA approval of TENEO represents a major milestone for the advancement of laser vision correction technology in the United States,” said George Waring IV, M.D., ophthalmologist and founder and medical director, Waring Vision Institute, Mt.

Human medicines European public assessment report (EPAR): Pregabalin Zentiva, pregabalin, Date of authorisation: 17/07/2015, Revision: 16, Status: Authorised

Retrieved on: 
Friday, January 5, 2024
Medical Subject Headings, Marketing, European Commission, Agency, Neuropathic pain, INN, Risk, ATC, Capsule, International, European, Spinal cord, Language, Butyric acid, Brain, Anxiety disorder, Anxiety, GAD, Nervous, Peripheral neuropathy, Zentiva, Select, Committee, Patient, Risk management, Anatomy, Medicine, IIA, CHMP, Medical device

Human medicines European public assessment report (EPAR): Pregabalin Zentiva, pregabalin, Date of authorisation: 17/07/2015, Revision: 16, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Pregabalin Zentiva, pregabalin, Date of authorisation: 17/07/2015, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Qutenza, capsaicin, Date of authorisation: 15/05/2009, Revision: 19, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Medical Subject Headings, Capsaicin, Marketing, European Commission, INN, HIV/AIDS, Infection, Diabetic neuropathy, ATC, Pain, Varicella zoster virus, International, European, Diabetes, Language, Shingles, Red, TRPV1, Trigeminal neuralgia, Neuropathic pain, HIV, Select, Committee, Patient, Risk management, Anatomy, Medicine, IIA, CHMP, Skin, Medical device

Human medicines European public assessment report (EPAR): Qutenza, capsaicin, Date of authorisation: 15/05/2009, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Qutenza, capsaicin, Date of authorisation: 15/05/2009, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Lyrica, pregabalin, Date of authorisation: 05/07/2004, Revision: 62, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Medical Subject Headings, Marketing, European Commission, Neuropathic pain, INN, Tetraplegia, Allergy, ATC, Pain, Capsule, International, European, Spinal cord, Language, Brain, Somnolence, Shingles, Diabetes, Anxiety disorder, Nerve, Dizziness, Anxiety, Anticonvulsant, Water, GAD, Nervous, Peripheral neuropathy, Diabetic neuropathy, Select, Committee, Anatomy, Medicine, Chronic pain, Seizure, IIA, CHMP, Medical device

Human medicines European public assessment report (EPAR): Lyrica, pregabalin, Date of authorisation: 05/07/2004, Revision: 62, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Lyrica, pregabalin, Date of authorisation: 05/07/2004, Revision: 62, Status: Authorised

Human medicines European public assessment report (EPAR): Pregabalin Pfizer, pregabalin, Date of authorisation: 10/04/2014, Revision: 30, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Medical Subject Headings, Marketing, Pfizer, European Commission, Agency, Neuropathic pain, INN, ATC, Pain, Capsule, International, European, Spinal cord, Diabetes, Language, Butyric acid, Brain, Somnolence, Shingles, Anxiety disorder, Nerve, Dizziness, Anxiety, Water, GAD, Nervous, CHMP, Peripheral neuropathy, Select, Risk management, Anatomy, Medicine, Chronic pain, Seizure, IIA, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Pregabalin Pfizer, pregabalin, Date of authorisation: 10/04/2014, Revision: 30, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Pregabalin Pfizer, pregabalin, Date of authorisation: 10/04/2014, Revision: 30, Status: Authorised

Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting

Retrieved on: 
Monday, December 4, 2023
Epilepsy, Pain, Disease, Chemotherapy, Chemotherapy-induced peripheral neuropathy, CIPN, Trevena, Neuropathic pain, Central nervous system disease, CNS, Bangladesh Technical Education Board, Poster, American College, Single, NIH, Patient, Central nervous system, Senior, Vaccine

CHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced a poster presentation at the 62nd Annual Meeting for the American College of Neuropsychopharmacology (ACNP). The conference is being held from December 3rd to 6th, 2023.

Key Points: 
  • CHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced a poster presentation at the 62nd Annual Meeting for the American College of Neuropsychopharmacology (ACNP).
  • The poster discussed the potential utility of TRV045 for the treatment of chemotherapy-induced peripheral neuropathy (CIPN) using an established nonclinical model.
  • CIPN is a nerve-damaging side effect of antineoplastic agents and occurs in approximately 70% of oncology patients undergoing chemotherapy.
  • Oral administration of TRV045 reduced mechanical and cold stimulus-evoked nociception in a dose-related manner in a mouse model of CIPN.

Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

Retrieved on: 
Thursday, November 30, 2023
T1DM, Food, FDA, AAK1, Type, Lexicon Pharmaceuticals, Patient, Dose-ranging study, Neuropathic pain, Extension, Trial of the century, Diagnosis, PROGRESS, Safety, T2DM, Fast Track, Pharmaceutical industry

THE WOODLANDS, Texas, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has enrolled the first patient in PROGRESS (A Phase 2b, Dose-ranging, Randomized, Double-blind, PlacebO-controlled, Parallel-GRoup, MulticEnter Study with an Open-label Extension in PatientS with Diabetic Peripheral Neuropathic Pain) studying LX9211, a potent, orally-delivered, selective, investigational small molecule inhibitor of adaptor-associated kinase 1 (AAK1).

Key Points: 
  • PROGRESS will enroll adult patients with a diagnosis of type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) with moderate to severe DPNP.
  • The primary endpoint of PROGRESS is a reduction of Average Daily Pain Score (ADPS), consistent with the primary endpoint achieved in the successful RELIEF-DPN-1 Phase 2a proof-of-concept study and, informed by regulatory feedback, the primary endpoint planned for Phase 3 studies of LX9211 in DPNP.
  • The placebo-controlled treatment period of PROGRESS is intended to identify the optimal dosing for Phase 3 studies.
  • The open-label extension is expected to run in parallel with planned next-stage Phase 3 studies, supporting long-term safety requirements for regulatory approval.

Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain

Retrieved on: 
Wednesday, December 27, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Diabetic neuropathy, LID, Pregabalin, Depression, Pain, Pain management, Gold, MD, Doctor of Philosophy, Chung, Gabapentin, Nerve, Patent, University, Anxiety, Neuropathic pain, CNS, Anesthesiology, Hyperalgesia, European Patent Convention, NMDAR, Central nervous system, Allodynia, EPO, Journal, Pharmacology, Levodopa-induced dyskinesia, Pharmaceutical industry

The patent, once granted, will not expire until at least 2034 and will become part of Vistagen’s global patent portfolio on therapeutic uses and manufacturing techniques for AV-101.

Key Points: 
  • The patent, once granted, will not expire until at least 2034 and will become part of Vistagen’s global patent portfolio on therapeutic uses and manufacturing techniques for AV-101.
  • In the study, AV-101 prodrug was systematically administered in four rat models of pain to examine its analgesic and behavioral profile.
  • The preclinical study was conducted by Tony L. Yaksh, PhD, Professor of Anesthesiology and Pharmacology at the University of California, San Diego.
  • Vistagen plans to seek potential strategic collaborations to further advance the clinical development and commercialization of AV-101.

Center for Pain Management Expands Clinic in Lafayette, Indiana

Retrieved on: 
Tuesday, December 19, 2023
Patient, Neck pain, Pain management, Pain, Chronic pain, Society, CRPS, Accident, CFP, Neuropathic pain, Human, Public key certificate, Nursing

LAFAYETTE, Ind., Dec. 19, 2023 /PRNewswire/ -- Center for Pain Management (CFP) is excited to announce the expansion of its clinic in Lafayette, Indiana, doubling in size to allow the clinic to meet the pain needs of the Greater Lafayette area and surrounding communities.

Key Points: 
  • LAFAYETTE, Ind., Dec. 19, 2023 /PRNewswire/ -- Center for Pain Management (CFP) is excited to announce the expansion of its clinic in Lafayette, Indiana, doubling in size to allow the clinic to meet the pain needs of the Greater Lafayette area and surrounding communities.
  • Leading the Lafayette clinic is Dr. Joseph Rutledge, a highly qualified medical professional in Anesthesiology with specialized expertise in Pain Management.
  • Dr. Rutledge is fellowship trained and Board Certified by the American Board of Anesthesiology, with additional qualifications in Pain Management.
  • The newly expanded Lafayette clinic will provide a holistic approach to pain management, offering services such as minimally invasive procedures, physical therapy, and psychological support.